Stewart Cole: Difference between revisions
No edit summary |
|||
| Line 21: | Line 21: | ||
==Career and research== |
==Career and research== |
||
Stewart Cole is a |
Stewart Cole is a full professor at the [[École polytechnique fédérale de Lausanne]] (EPFL), where he is Director of the Global Health Institute. He was previously acting President, Senior Vice President and Scientific Director of the [[Pasteur Institute]] in [[Paris]]. He has been active in [[infectious disease]] research for more than 30 years, in particular in the field of [[tuberculosis]]. |
||
He was scientific coordinator for the New Medicines For Tuberculosis project (NM4TB),<ref>{{cite web| url = http://www.mm4tb.org/nm4tb/|title=New Medicines For Tuberculosis}}</ref> running from 2006 to 2009 and was the coordinator of the follow-up More Medicines For Tuberculosis project (MM4TB)<ref>{{cite web| url = http://www.mm4tb.org|title=More Medicines For Tuberculosis}}</ref> running from 2011 to 2016 in the context of the FP7 European Union's Research and Innovation funding programme. |
He was scientific coordinator for the New Medicines For Tuberculosis project (NM4TB),<ref>{{cite web| url = http://www.mm4tb.org/nm4tb/|title=New Medicines For Tuberculosis}}</ref> running from 2006 to 2009 and was the coordinator of the follow-up More Medicines For Tuberculosis project (MM4TB)<ref>{{cite web| url = http://www.mm4tb.org|title=More Medicines For Tuberculosis}}</ref> running from 2011 to 2016 in the context of the FP7 European Union's Research and Innovation funding programme. |
||
Revision as of 13:47, 16 October 2017
Stewart Cole | |
|---|---|
| Born | 14 January 1955  Penzance |
| Employer |
|
| Awards |
|
| Scientific career | |
| Thesis | Biochemical and genetic studies of the fumarate reductase of Escherichia coli K12 (1979) |
| Website | people |
| Position held | director (Pasteur Institute, 2018–) |
Stewart Thomas Cole FRS is a British microbiologist.[1]
Education
Professor Cole studied microbiology in the UK at the University of Wales, prior to earning his Doctor of Philosophy in molecular genetics from the University of Sheffield in 1979. Subsequently, he embarked on a career as a research scientist at the University of Umeå (Sweden) and the Max-Planck-Institut in Tübingen (Germany).
Career and research
Stewart Cole is a full professor at the École polytechnique fédérale de Lausanne (EPFL), where he is Director of the Global Health Institute. He was previously acting President, Senior Vice President and Scientific Director of the Pasteur Institute in Paris. He has been active in infectious disease research for more than 30 years, in particular in the field of tuberculosis.
He was scientific coordinator for the New Medicines For Tuberculosis project (NM4TB),[2] running from 2006 to 2009 and was the coordinator of the follow-up More Medicines For Tuberculosis project (MM4TB)[3] running from 2011 to 2016 in the context of the FP7 European Union's Research and Innovation funding programme.
For nearly four decades Professor Stewart Cole has enjoyed a rich and varied career working and teaching in universities and research institutes in several different European countries. His research accomplishments in microbiology have been widely acclaimed and are of direct relevance to global health and disease-control in both the developing world and the industrialized nations.
Professor Cole has supervised over 30 students for MS and PhD degrees and trained 40 postdoctoral fellows and clinicians. As a result of their work, he has published over 300 scientific papers and review articles (h-index >77), and holds several patents that have found direct application in human medicine.
Professor Cole has successfully led three major drug discovery consortia funded by the European Commission (FP5, 6, 7) and his laboratory has attracted research grants from diverse sources including the Agence Nationale de Recherche, the Bill and Melinda Gates Foundation, INSERM, the NIH, the Swiss National Science Foundation, the Wellcome Trust, and the World Health Organization.
Stewart Cole is appointed President of the Institut Pasteur on 13 October 2017.
Awards
- 2002 Marjory Stephenson Prize from the Society for General Microbiology [4]
- 2009 Kochon Prize from the World Health Organization’s STOP-TB Partnership [5]
- 2014 Emil von Behring Prize from the University of Marburg [6]
- 2016 Gardner Middlebrook Award, 37th Annual Congress of the European Society of Mycobacteriology (3 July 2016; Catania, Italy).[7]
References
- ^ http://cole-lab.epfl.ch/
- ^ "New Medicines For Tuberculosis".
- ^ "More Medicines For Tuberculosis".
- ^ "Marjory Stephenson Prize Lecture". Society for General Microbiology. Retrieved 15 February 2017.
- ^ "2009 Kochon Prize Award Winners". STOP-TB Partnership. Retrieved 29 March 2017.
- ^ "Warm congratulations to Stewart Cole". EPFL. Retrieved 15 February 2017.
- ^ "Stewart Cole receives the Gardner Middlebrook Award 2016". EPFL. Retrieved 15 February 2017.
External links
- http://sciencewatch.com/ana/st/tub/09marSTTubCole/
- http://www2.kenes.com/fems2011/sci/Documents/Stewart_Cole.pdf
- http://cole-lab.epfl.ch/
| International | |
|---|---|
| National | |
| Academics | |
 | This article about a biologist from the United Kingdom is a stub. You can help Wikipedia by expanding it. |